In 12-month-old female APP/PS1/tau AD mouse model, neurofibrillary tangles, amyloid plaques, and neuroinflammation in the hippocampi have been reduced by lixisenatide (Cai et al., 2018). This evidence concerns the gene MAPT and Alzheimer disease.